ColVI myopathies: where do we stand, where do we go?

Area of Science:

• Genetics
• Molecular Biology
• Neuromuscular Disorders

Background:

• Collagen VI myopathies encompass a spectrum from Ullrich congenital muscular dystrophy to Bethlem myopathy.
• These disorders share features with other myopathies, complicating differential diagnosis.
• Advances in understanding molecular pathogenesis have emerged over the past decade.

Purpose of the Study:

• To review the current state of diagnosis and research in Collagen VI myopathies.
• To highlight recent findings in molecular pathogenesis and cellular dysfunction.
• To identify potential therapeutic avenues.

Main Methods:

• Review of existing literature on Collagen VI myopathies.
• Analysis of genotype-phenotype correlations.
• Examination of findings from animal models and patient samples.

Main Results:

• Numerous mutations in COL6A1, COL6A2, and COL6A3 genes have been identified, many with dominant-negative effects.
• Genotype-phenotype correlations indicate that specific mutation types are linked to disease severity and onset.
• Mitochondrial dysfunction and defects in skeletal muscle autophagy have been recently identified.

Conclusions:

• Collagen VI myopathies are a significant area of research with evolving diagnostic and therapeutic landscapes.
• Understanding molecular mechanisms, including mitochondrial and autophagic pathways, is crucial.
• Recent discoveries offer promising directions for future therapeutic interventions.